Page last updated: 2024-12-05
triglyme
Description
Triglyme, also known as tris(2-methoxyethyl) ether, is a non-toxic, colorless liquid with a high boiling point and low viscosity. It is a highly polar aprotic solvent with excellent solvating properties for a wide range of compounds. It is commonly used as a solvent in various chemical reactions, including polymerization, metal complexation, and organic synthesis. Triglyme is also used as a dielectric fluid in capacitors and as a plasticizer in polymers. Its synthesis involves the condensation reaction of ethylene glycol with 2-methoxyethanol. Triglyme is studied due to its unique properties as a solvent, its biocompatibility, and its potential applications in various fields such as lithium-ion batteries, fuel cells, and pharmaceutical synthesis. Its high polarity allows for the dissolution of a wide range of ionic compounds, and its low viscosity ensures rapid mass transfer in reactions. Triglyme is particularly relevant in lithium-ion batteries due to its ability to dissolve lithium salts, enhancing conductivity and battery performance.'
triglyme : A polyether that consists of dodecane in which the carbon atoms at positions 2, 5, 8 and 11 are replaced by oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 8189 |
| CHEMBL ID | 1235255 |
| CHEBI ID | 44842 |
| SCHEMBL ID | 16126 |
| MeSH ID | M0151527 |
Synonyms (62)
| Synonym |
|---|
| CHEMBL1235255 |
| glyme-3 |
| nsc-66400 |
| ethane,2-bis(2-methoxyethoxy)- |
| triglyme |
| glyme-4 |
| 112-49-2 |
| triethylene glycol dimethyl ether |
| ansul ether 161 |
| nsc66400 |
| 2,8,11-tetraoxadodecane |
| 1,2-bis(2-methoxyethoxy)ethane |
| 2,5,8,11-tetraoxadodecane |
| pg5 , |
| 1-methoxy-2-[2-(2-methoxy-ethoxy]-ethane |
| nsc 66400 |
| brn 1700630 |
| tegdime |
| ethane, 1,2-bis(2-methoxyethoxy)- |
| einecs 203-977-3 |
| ai3-28582 |
| glycol, triethylene-, dimethyl ether |
| DB02078 |
| 1-methoxy-2-[2-(2-methoxyethoxy)ethoxy]ethane |
| dimethyl ether of triethylene glycol |
| NCGC00164017-01 |
| CHEBI:44842 , |
| glyme 4 |
| B0496 |
| FT-0659858 |
| A802587 |
| NCGC00164017-02 |
| AKOS009158244 |
| unii-32yxg88kk0 |
| ec 203-977-3 |
| 32yxg88kk0 , |
| dtxsid8026224 , |
| tox21_300509 |
| cas-112-49-2 |
| dtxcid206224 |
| NCGC00254323-01 |
| SCHEMBL16126 |
| triglyme [mi] |
| 1,2-bis(methoxyethoxy)ethane |
| (ch3o(ch2)2och2)2 |
| triethylene glycol dimethyl ether (stabilized with bht) |
| triethylene glycol dimethylether |
| triethyleneglycol dimethyl ether |
| mfcd00008504 |
| triethylene glycol dimethyl ether, analytical reference material |
| triethylene glycol dimethyl ether, reagentplus(r), 99% |
| triethylene glycol dimethyl ether, vetec(tm) reagent grade, 98% |
| FT-0755020 |
| E75964 |
| 1,2-bis(2-methoxyethoxy) ethane, reagent |
| Q2453066 |
| 2,5,8,11-tetraoxadodecane;1,2-bis(2-methoxyethoxy)ethane;triethylene glycol dimethyl ether;1,2bis(2methoxyethoxy)ethane;triethylene glycoldimethylether (tegdme);2,5,8,11-tetraoxadodecane 1,2-bis(2-methoxyethoxy)ethane triethylene glycol dimethyl ether 1,2 |
| 1-methoxy-2-[2-(2-methoxy-ethoxy)-ethoxy]-ethane |
| EN300-40253 |
| triethylene glycol dimethyl ether 100 microg/ml in acetonitrile |
| CS-W017328 |
| Z409380232 |
Research Excerpts
Toxicity
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| "The Rai and Van Ryzin dose-response model proposed for teratology experiments has been characterized for its appropriateness and applicability in modeling the dichotomous response data from developmental toxicity studies." | ( Characterization of a developmental toxicity dose-response model.
Faustman, EM; Kimmel, CA; Smith, WP; Wellington, DG, 1989) | 0.28 |
| "Time-mated CD-1 mice were orally dosed on gestation day 11 (plug = 0) with distilled water (control) or one of four glycol ethers at a dose of 4 mmol/kg: ethylene glycol monomethyl ether (EGME, 304 mg/kg), ethylene glycol dimethyl ether (EGdiME, 361 mg/kg), diethylene glycol dimethyl ether (diEGdiME, 537 mg/kg), triethylene glycol dimethyl ether (triEGdiME, 713 mg/kg)." | ( Relative potency of four ethylene glycol ethers for induction of paw malformations in the CD-1 mouse.
Eisenmann, CJ; Hardin, BD, 1987) | 0.27 |
Roles (1)
| Role | Description |
|---|
| solvent | A liquid that can dissolve other substances (solutes) without any change in their chemical composition. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| polyether | Any ether that contains more than one ether linkage. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (2)
Potency Measurements
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 43.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 43.83 (24.57) | | Research Supply Index | 2.48 (2.92) | | Research Growth Index | 4.45 (4.65) | | Search Engine Demand Index | 59.80 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |